Urology News, Research Studies | Urological Disease Treatment

Urology News



Olaparib Approved for Metastatic Castration-Resistant Prostate Cancer

The FDA has approved Lynparza® (olaparib; AstraZeneca and Merck) for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.
Next post in Upper tract urothelial carcinoma